The main office of represented VC is situated in the London. The fund was located in Europe if to be more exact in United Kingdom.
The fund is constantly included in less than 2 investment rounds annually. The usual things for fund are deals in the range of more than 100 millions dollars. This Falcon Capital works on 5 percentage points less the average amount of lead investments comparing to the other organizations. The top activity for fund was in 2015. The real fund results show that this VC is 2 percentage points less often commits exit comparing to other companies. The typical startup value when the investment from Falcon Capital is more than 1 billion dollars. The top amount of exits for fund were in 2017.
The overall number of key employees were 2.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Falcon Capital, startups are often financed by Matrix Partners India, Tiger Global Management, Sequoia Capital India. The meaningful sponsors for the fund in investment in the same round are Sequoia Capital India, Tiger Global Management, Phoenix Partners Group. In the next rounds fund is usually obtained by Kleiner Perkins, Catamount Ventures, Phoenix Partners Group.
We can highlight the next thriving fund investment areas, such as Information Technology, Ride Sharing. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight Olacabs, Koudai Gouwu, Juno.
Funds with similar focus
|AlphaLab||Pennsylvania, Pittsburgh, United States|
|Asia Capital||Colombo, Sri Lanka, Western Province|
|Baichuan Huida Touzi||China, Guangdong, Tianjin|
|Capital Medica Ventures||Chiyoda, Japan|
|China Telenet Ventures||-|
|Co-Share capital||China, Guangdong, Guangzhou|
|Ferring Pharmaceuticals||Saint-prex, Switzerland, Vaud|
|Goat Capital||California, San Francisco, United States|
|Hongjiao Capital||China, Ningbo, Zhejiang|
|Linden Venture Fund||Chicago, Illinois, United States|
|Money Forward||Chiyoda, Japan|
|New Science Ventures||New York, New York, United States|
|Promus Capital||Chicago, Illinois, United States|
|Sansar Capital||Central, Central Region, Singapore|
|Taiko Pharmaceutical||Japan, Osaka, Osaka Prefecture|
|Xuwei Investment||China, Shanghai|
|$200M||29 Aug 2022||New York, New York, United States|
|$500K||04 Jan 2020||London, England, United Kingdom|
ConversionPoint Technologies Inc.
|$10M||01 Jul 2018||California, United States|
|$7M||18 May 2018||Henderson, Nevada, United States|
|$5M||17 Jan 2017||New York, New York, United States|
|$25M||15 Oct 2016||Karnataka|
|01 Jun 2016||New York, New York, United States|
|$500M||17 Nov 2015||Bengaluru, Karnataka, India|
Mswipe Technologies Private Limited
|$25M||22 Jul 2015||India, Maharashtra|
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.